NIP
BPMC

Nicholas Investment Partners’s Blueprint Medicines BPMC Stock Holding History

Nicholas Investment Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,611
Closed -$4.38M – 221
2024
Q2 		$4.38M Buy
+40,611
New +$4.06M 0.45% 81
2019
Q3 		– Sell
-106,956
Closed -$10.1M – 203
2019
Q2 		$10.1M Buy
106,956
+32,505
+44% +$2.68M 0.93% 20
2019
Q1 		$5.96M Buy
+74,451
New +$5.5M 0.53% 43
2018
Q4 		– Sell
-48,921
Closed -$3.82M – 218
2018
Q3 		$3.82M Sell
48,921
-441
-0.9% -$30.6K 0.31% 129
2018
Q2 		$3.13M Buy
49,362
+14,806
+43% +$1.18M 0.22% 149
2018
Q1 		$3.17M Sell
34,556
-3,199
-8% -$276K 0.23% 149
2017
Q4 		$2.85M Buy
37,755
+361
+1% +$25.4K 0.19% 172
2017
Q3 		$2.6M Buy
37,394
+57
+0.2% +$3.05K 0.18% 190
2017
Q2 		$1.89M Buy
37,337
+15,339
+70% +$651K 0.13% 211
2017
Q1 		$878K Buy
+21,998
New +$788K 0.06% 241

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nicholas Investment Partners's BPMC Position: Q3 2024 in Review

Nicholas Investment Partners sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 40,611 shares — an estimated $4.38M sold.

Nicholas Investment Partners first reported a position in BPMC in Q1 2017 and held it in 10 quarters. The position peaked at $10.1M in Q2 2019. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Nicholas Investment Partners reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 40,611 Blueprint Medicines shares in Q3 2024, an estimated $4.38M.
  • Nicholas Investment Partners first reported a position in Blueprint Medicines in Q1 2017 and held it in 10 quarters.
  • Nicholas Investment Partners's Blueprint Medicines position peaked at $10.1M in Q2 2019.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Nicholas Investment Partners's 13F filing for Q3 2024, filed 12 Nov 2024.